Clinical Trial Update: Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a gemcitabine/docetaxel and oxaliplatin-based chemo/radiation regimen for border-line resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Benaroya Research Institute | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED